JPWO2020252294A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020252294A5 JPWO2020252294A5 JP2021573841A JP2021573841A JPWO2020252294A5 JP WO2020252294 A5 JPWO2020252294 A5 JP WO2020252294A5 JP 2021573841 A JP2021573841 A JP 2021573841A JP 2021573841 A JP2021573841 A JP 2021573841A JP WO2020252294 A5 JPWO2020252294 A5 JP WO2020252294A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyldiyl
- peg
- immunoconjugate
- pep
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861139P | 2019-06-13 | 2019-06-13 | |
| US62/861,139 | 2019-06-13 | ||
| US202062963884P | 2020-01-21 | 2020-01-21 | |
| US62/963,884 | 2020-01-21 | ||
| PCT/US2020/037477 WO2020252294A1 (en) | 2019-06-13 | 2020-06-12 | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022537158A JP2022537158A (ja) | 2022-08-24 |
| JPWO2020252294A5 true JPWO2020252294A5 (es) | 2023-06-16 |
Family
ID=71608047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573841A Pending JP2022537158A (ja) | 2019-06-13 | 2020-06-12 | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200390899A1 (es) |
| EP (1) | EP3983082A1 (es) |
| JP (1) | JP2022537158A (es) |
| KR (1) | KR20220034784A (es) |
| CN (1) | CN114585390A (es) |
| AU (1) | AU2020291014A1 (es) |
| BR (1) | BR112021025034A2 (es) |
| CA (1) | CA3142887A1 (es) |
| IL (1) | IL288816A (es) |
| MX (1) | MX2021015221A (es) |
| TW (1) | TW202112752A (es) |
| WO (1) | WO2020252294A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3484518A4 (en) | 2016-07-07 | 2020-04-22 | The Board of Trustees of the Leland Stanford Junior University | ANTIBODY ADJUVANT CONJUGATES |
| WO2020190725A1 (en) | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2021081407A1 (en) | 2019-10-25 | 2021-04-29 | Bolt Biotherapeutics, Inc. | Thienoazepine immunoconjugates, and uses thereof |
| EP4093510A1 (en) * | 2020-01-21 | 2022-11-30 | Bolt Biotherapeutics, Inc. | Anti-pd-l1 antibodies |
| EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| JP2023524271A (ja) * | 2020-05-08 | 2023-06-09 | ボルト バイオセラピューティクス、インコーポレーテッド | エラスターゼ－基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用 |
| WO2022006327A1 (en) | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Anti-asgr1 antibody conjugates and uses thereof |
| WO2022036101A1 (en) * | 2020-08-13 | 2022-02-17 | Bolt Biotherapeutics, Inc. | Pyrazoloazepine immunoconjugates, and uses thereof |
| CN116897054A (zh) * | 2020-12-11 | 2023-10-17 | 博尔特生物治疗药物有限公司 | 抗her2免疫缀合物及其用途 |
| US20220195066A1 (en) * | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| WO2022125891A2 (en) * | 2020-12-11 | 2022-06-16 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| US20240091370A1 (en) * | 2020-12-11 | 2024-03-21 | Bolt Biotherapeutics, Inc. | Anti-her2 immunoconjugates, and uses thereof |
| IL303491A (en) * | 2020-12-11 | 2023-08-01 | Bolt Biotherapeutics Inc | Anti-PD-L1 immunoconjugates and uses thereof |
| EP4277925A1 (en) * | 2021-01-14 | 2023-11-22 | Gritstone bio, Inc. | Multi-specific antibodies and methods of use |
| JP2024512056A (ja) * | 2021-03-26 | 2024-03-18 | ボルト バイオセラピューティクス、インコーポレーテッド | ２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用 |
| EP4313162A1 (en) * | 2021-03-26 | 2024-02-07 | Bolt Biotherapeutics, Inc. | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
| WO2023076599A1 (en) | 2021-10-29 | 2023-05-04 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| TW202333737A (zh) * | 2021-12-16 | 2023-09-01 | 大陸商映恩生物製藥（蘇州）有限公司 | Ｔｌｒ調節劑及其用途 |
| TW202339806A (zh) * | 2022-02-09 | 2023-10-16 | 美商博特生物治療公司 | ８—磺醯基—苯并氮呯免疫結合物及其用途 |
| WO2023154302A1 (en) * | 2022-02-09 | 2023-08-17 | Bolt Biotherapeutics, Inc. | Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses |
| WO2023232142A1 (zh) * | 2022-06-02 | 2023-12-07 | 映恩生物制药（苏州）有限公司 | 一种药物化合物及其用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US723288A (en) | 1901-10-26 | 1903-03-24 | Harry South Lewis | Cipher-key for cryptographic codes. |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| DE69907439T3 (de) | 1998-05-06 | 2014-01-02 | Genentech, Inc. | Reinigung von proteinen durch ionenaustauschchromatographie |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US7416726B2 (en) | 2000-04-13 | 2008-08-26 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
| US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| JP5399712B2 (ja) | 2005-12-21 | 2014-01-29 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 可溶性ｃｅａに対する抵抗性を有する医薬組成物 |
| AU2008251608B2 (en) | 2007-05-08 | 2014-03-27 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| CN102822199B (zh) | 2010-02-04 | 2014-10-15 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| CA2816426A1 (en) | 2010-11-17 | 2012-06-07 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| PL2681244T3 (pl) | 2011-03-02 | 2018-04-30 | Roche Glycart Ag | Przeciwciała przeciwko antygenowi rakowo-płodowemu |
| MX348578B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
| PL2740793T3 (pl) | 2011-08-04 | 2018-04-30 | Toray Industries, Inc. | Kompozycja leku do leczenia i/lub zapobiegania nowotworowi |
| WO2013018889A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| CA2844030C (en) | 2011-08-04 | 2019-09-03 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| AU2013223147B2 (en) | 2012-02-21 | 2017-10-05 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| IN2014KN01713A (es) | 2012-02-21 | 2015-10-23 | Toray Industries | |
| AU2013223161B2 (en) | 2012-02-21 | 2017-10-19 | Toray Industries, Inc. | Medicinal composition for treating and/or preventing cancer |
| AU2013223137B2 (en) | 2012-02-21 | 2017-10-19 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| US9753038B2 (en) | 2012-07-19 | 2017-09-05 | Toray Industries, Inc. | Method for detecting cancer via measurement of caprin-1 expression level |
| CA2879304C (en) | 2012-07-19 | 2020-07-14 | Toray Industries, Inc. | Method for detecting cancer |
| EA039377B1 (ru) | 2012-11-20 | 2022-01-20 | Санофи | Антитела к ceacam5 и их применения |
| AU2014303375B2 (en) | 2013-08-09 | 2019-07-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| PE20210168A1 (es) | 2014-02-10 | 2021-01-28 | Merck Patent Gmbh | INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) |
| PE20170782A1 (es) | 2014-11-21 | 2017-07-04 | Bristol Myers Squibb Co | Anticuerpos frente a cd73 y usos de los mismos |
| CN107148417B (zh) * | 2014-12-18 | 2020-09-08 | 豪夫迈·罗氏有限公司 | 苯并氮杂*磺酰胺化合物 |
| KR20190075921A (ko) | 2016-10-28 | 2019-07-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| EP3574018A4 (en) * | 2017-01-27 | 2020-10-07 | Silverback Therapeutics, Inc. | CONJUGATES TARGETING TUMORS AND THEIR METHODS OF USE |
| SG10202110182PA (en) * | 2017-03-15 | 2021-10-28 | Silverback Therapeutics Inc | Benzazepine compounds, conjugates, and uses thereof |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| WO2019118884A1 (en) * | 2017-12-15 | 2019-06-20 | Silverback Therapeutics, Inc. | Antibody construct-drug conjugate for the treatment of hepatitis |
| KR20210081339A (ko) * | 2018-09-12 | 2021-07-01 | 실버백 테라퓨틱스, 인크. | 치환된 벤즈아제핀 화합물, 접합체, 및 이의 용도 |
| WO2020056194A1 (en) * | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
| MX2021002764A (es) * | 2018-09-12 | 2021-05-12 | Silverback Therapeutics Inc | Composiciones para el tratamiento de enfermedades con conjugados inmunoestimuladores. |
-
2020
- 2020-06-12 AU AU2020291014A patent/AU2020291014A1/en active Pending
- 2020-06-12 CN CN202080053101.9A patent/CN114585390A/zh active Pending
- 2020-06-12 US US16/900,193 patent/US20200390899A1/en active Pending
- 2020-06-12 BR BR112021025034A patent/BR112021025034A2/pt unknown
- 2020-06-12 EP EP20740106.8A patent/EP3983082A1/en active Pending
- 2020-06-12 MX MX2021015221A patent/MX2021015221A/es unknown
- 2020-06-12 TW TW109119949A patent/TW202112752A/zh unknown
- 2020-06-12 KR KR1020227001083A patent/KR20220034784A/ko active Search and Examination
- 2020-06-12 CA CA3142887A patent/CA3142887A1/en active Pending
- 2020-06-12 WO PCT/US2020/037477 patent/WO2020252294A1/en unknown
- 2020-06-12 JP JP2021573841A patent/JP2022537158A/ja active Pending
-
2021
- 2021-12-09 IL IL288816A patent/IL288816A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020252294A5 (es) | ||
| JP2023002615A5 (es) | ||
| JP2019520352A5 (es) | ||
| RU2018119296A (ru) | Конъюгаты антитела, содержащие агонисты толл-подобного рецептора | |
| JP2020019787A5 (es) | ||
| JP2019532056A5 (es) | ||
| HRP20200032T1 (hr) | Antitijelo lijek konjugati | |
| JP2017518304A5 (es) | ||
| JP2018516243A5 (es) | ||
| JP2012522513A5 (es) | ||
| JP5593488B2 (ja) | 癌間質の構成因子に対して特異的結合能を有する物質と抗腫瘍性化合物との複合体による新規の癌ターゲティング治療 | |
| KR20140139480A (ko) | 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법 | |
| JP2018511628A5 (es) | ||
| CA3090251A1 (en) | Glypican 3 antibodies and conjugates thereof | |
| US20230295346A1 (en) | Prodruggable antibodies, prodrugs thereof, and methods of use and making | |
| HRP20230275T1 (hr) | Antitijelo-lijek konjugati koji sadrže derivate ekteinascidina | |
| JP2016521262A (ja) | 癌のための併用療法 | |
| WO2023131219A1 (en) | Conjugates, compositions and methods of use | |
| JPWO2019217591A5 (es) | ||
| JPWO2021067242A5 (es) | ||
| JP2019536780A (ja) | Ｍｅｔ抗体薬物複合体 | |
| JPWO2021213434A5 (es) | ||
| RU2016119491A (ru) | Конъюгаты антитела к efna4 с лекарственным средством | |
| JPWO2021226440A5 (es) | ||
| JPWO2021081407A5 (es) |